Xuesaitong Injection Collaborative Love Tongli Preliminary Clinical Studies Of Intravenous Thrombolysis In Acute Cerebral Infarction

This paper includes three parts: documental research, a Meta analysis of TCM for acute cerebral infarction with intravenous thrombolysis and clinical research.The clinical research includes:Aim: To evaluate the efficacy and mechanism of combined recombinant tissue plasminogen activator(r-tPA) and XUESAITONG thtombolytic therapy, To investigate the distributions of syndrome in patients after throbolytic therapy, To evaluate the healing effect of the treatment of invigorate the circulation ofblood and Collaterals and changing of syndrome in early stageMethods: The patients who suited for the standard were divided into two groups-Combined recombinant tissue plasminogen activator(r-tP A) and XUESAITONG group (Group A) and control group r-tPA group (Group B). Group Areceived r-tPAand XUESAITONG That given in a dose of 20Qmg, daily, for 15 days, Group B received r-tPA at 50mg, r-tPAat 8mg was injected intravenously in a bolus at first and then the rest was given over 60 minutes. Both groups were followed by subcutaneous injection of low molecular weight heparin (0.4ml, twice daily) for 7 days and Asprrine teken orally after thrombllytic treatment 24 h. The dosage and usage of r-tPA in group A was the same as that in group B.To have statistical analysis on hemorheolgy and plateletcount of patients after treatment for 7 days and 30 days.The fluctuation of every index were observedThe Chinese stroke scale (CSS) and Barthel Index (Bl) of patients in two groups were used to evaluate the recovery of neurological functions after treatment for 24 hours and 7 days and 30 days.And observe the syndrome ofTCM in two group before treatment and after treatment for 7 days and 30 days.ResultCompared with Group B,The whole blood viscosity,viscosity of plasma red blood cell aggregation index hematocrit,fibmogen, plateletcount of Group A were reduced in varing degrees after treatmnt for 7 days and 30 days In groupA,the CSS significant effective rate was 29.41 percent at 24 hours and 52.94 percent at 7days and 76.47 percent at 30days after thrombolysis. At 30 days BI significant effective rate was 52.94 percent In group B, the CSS significant effective rate was 3125 percent at 24 hours and 37.5 percent at 7 days and 43.75 percent at 30 days after thrombolysis. At 30 days3I significant effective rate was 25 percentAl 30 days significant effective rate in Group A was evidently higher than which in Group B(76.47 percent vs 43.75 percent, P<0.05).The total score of traditional medicine symptom descended after treatment based on symdrome differentiation in group A, especially in Blood stasis syndrome and phlegm syndrom at 30 days.Conclusion: Early intravenous thrombolysis with combined recombinant tissue plasminogen activator(r-tPA) and XUESAITONG for acute cerebral infarction is feasible and safty. The effect of combined recombinant tissue plasminogen activator(r-tPA) and XUESAITONG thrombolytic therapy is better than r-tPA Ihrombolytic therapy. Which may be attributed to the treatment of invigorate the circulation ofblood and Collaterals and the function of XUESATTONG it has effect of dissolving thrombus and resistting Platelet and thrombosis.It is necessary to carry out further clinicresearch on early intravenous thrombolysis with combined r-tPA and Chinese medicine for acute cerebral infarction.